Altimmune, Inc. ALT posted a loss for the second quarter on Tuesday.The company posted a quarterly loss of 27 cents per share, versus market estimates of a loss of 32 cents per share. The company's quarterly sales came in at $5.000K.“Pemvidutide demonstrated rapid and robust MASH effects, meaningful weight loss and impressive safety and tolerability in the recently reported results from the IMPACT Phase 2b trial,” said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. “We are prepari ...